JP2015508054A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508054A5
JP2015508054A5 JP2014553633A JP2014553633A JP2015508054A5 JP 2015508054 A5 JP2015508054 A5 JP 2015508054A5 JP 2014553633 A JP2014553633 A JP 2014553633A JP 2014553633 A JP2014553633 A JP 2014553633A JP 2015508054 A5 JP2015508054 A5 JP 2015508054A5
Authority
JP
Japan
Prior art keywords
cells
inhibitor
factor
combination
direct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508054A (ja
JP6034406B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2012/051157 external-priority patent/WO2012101181A1/en
Application filed filed Critical
Priority claimed from PCT/EP2012/061534 external-priority patent/WO2013110354A1/en
Publication of JP2015508054A publication Critical patent/JP2015508054A/ja
Publication of JP2015508054A5 publication Critical patent/JP2015508054A5/ja
Application granted granted Critical
Publication of JP6034406B2 publication Critical patent/JP6034406B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553633A 2012-01-25 2012-06-15 細胞移植のための組成物および方法 Expired - Fee Related JP6034406B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/051157 WO2012101181A1 (en) 2011-01-25 2012-01-25 Compositions and methods for cell transplantation
EPPCT/EP2012/051157 2012-01-25
PCT/EP2012/061534 WO2013110354A1 (en) 2012-01-25 2012-06-15 Compositions and methods for cell transplantation

Publications (3)

Publication Number Publication Date
JP2015508054A JP2015508054A (ja) 2015-03-16
JP2015508054A5 true JP2015508054A5 (enExample) 2015-07-02
JP6034406B2 JP6034406B2 (ja) 2016-11-30

Family

ID=46507976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553633A Expired - Fee Related JP6034406B2 (ja) 2012-01-25 2012-06-15 細胞移植のための組成物および方法

Country Status (5)

Country Link
US (1) US9775890B2 (enExample)
EP (1) EP2806879B1 (enExample)
JP (1) JP6034406B2 (enExample)
ES (1) ES2726802T3 (enExample)
WO (1) WO2013110354A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825252C (en) 2011-01-25 2018-10-16 Universite Catholique De Louvain Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation
CN104038425B (zh) * 2013-03-06 2018-01-02 阿里巴巴集团控股有限公司 转发以太网报文的方法和装置
DK3016665T3 (da) 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
EP2843416A1 (de) * 2013-09-02 2015-03-04 Siemens Healthcare Diagnostics Products GmbH Kontroll- und Kalibratormaterial für die Bestimmung von direkten Antikoagulanzien
MA45274A (fr) * 2016-03-02 2019-01-09 Univ Catholique Louvain Préparations améliorées de cellules progénitrices hépatiques adultes
CN110177871B (zh) * 2017-03-03 2023-05-09 日本乐敦制药株式会社 间充质干细胞和肝疾病治疗剂
US10567300B2 (en) 2017-11-22 2020-02-18 Cisco Technology, Inc. Layer 3 fair rate congestion control notification
US10785161B2 (en) 2018-07-10 2020-09-22 Cisco Technology, Inc. Automatic rate limiting based on explicit network congestion notification in smart network interface card
KR20220004977A (ko) * 2019-03-26 2022-01-12 프로메테라 테라푸틱스 에스에이 만성 간부전의 급성 악화를 치료하기 위한 성체 간 전구 세포
US10986026B2 (en) 2019-06-11 2021-04-20 Cisco Technology, Inc. Proportional integral based shaper for lossless output buffer
WO2021242783A1 (en) * 2020-05-26 2021-12-02 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9010552D0 (en) 1990-05-10 1990-07-04 Erba Carlo Spa Method for the recombinant production of hirudins and novel hirudins
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
DE10041402A1 (de) 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
DE10202982A1 (de) 2002-01-26 2003-07-31 Augustinus Bader Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit
US20060222640A1 (en) 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
EP1996013A4 (en) 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
WO2007071339A1 (en) * 2005-12-21 2007-06-28 Universite Catholique De Louvain Isolated liver stem cells
CA2825252C (en) 2011-01-25 2018-10-16 Universite Catholique De Louvain Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation

Similar Documents

Publication Publication Date Title
JP2015508054A5 (enExample)
JP2014508138A5 (enExample)
Samama The mechanism of action of rivaroxaban–an oral, direct Factor Xa inhibitor–compared with other anticoagulants
UY37565A (es) Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CL2011003276A1 (es) Compuesto amida del ácido {5-[4-{3,3-dimetll-azetidina-1-carbonil)-fenil]-[l,2,4]trlaz010[l,5-a]piridin-2-1i} clclopropanocarboxillco; inhibldor de jak1: composición farmacéutica que lo comprende: uso del compuesto en la profilaxis ylo tratamiento de afecciones inflamatorias, autolnmunltarias, proliferativas, entre otras.
TW201612167A (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane -2-carboxamides as dipeptidyl peptidase 1 inhibitors
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
Kim et al. The therapeutic effects of optimal dose of mesenchymal stem cells in a murine model of an elastase induced-emphysema
PE20141318A1 (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando acidos organicos
MX375836B (es) Composiciones y métodos para inhibir la expresión del gen de alfa-1 antitripsina.
PE20140616A1 (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
Ma et al. Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K
MY169330A (en) Method for inhibition of deubiquitinating activity
Li et al. HMGB1 affects the development of pulmonary arterial hypertension via RAGE.
Fu Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance
Chen et al. Exosomes derived from human umbilical cord mesenchymal stem cells protect against papain-induced emphysema by preventing apoptosis through activating VEGF-VEGFR2-mediated AKT and MEK/ERK pathways in rats
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
RU2012122793A (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
IN2014DN05784A (enExample)
MX2012009976A (es) Uretanos, ureas, amidinas e inhibidores relacionados del factor xa.
AR085265A1 (es) Composiciones farmaceuticas que contienen compuestos con selenita
Kupatt et al. Embryonic endothelial progenitor cell-mediated cardioprotection requires Thymosin β4
GB2549031A (en) Methods and drug therapies for patency of occluded blood vessels following angioplasty
Chiang et al. Metabolic alterations in HSCs during aging and leukemogenesis